Wave Life Sciences WVE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Wave Life Sciences's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Wave Life Sciences's additional paid-in capital?
- Wave Life Sciences (WVE) reported additional paid-in capital of $237.43M in Q1 2026.
- How has Wave Life Sciences's additional paid-in capital changed year-over-year?
- Wave Life Sciences's additional paid-in capital increased by 47.1% year-over-year, from $161.41M to $237.43M.
- What is the long-term trend for Wave Life Sciences's additional paid-in capital?
- Over 5 years (2020 to 2025), Wave Life Sciences's additional paid-in capital has grown at a 26.1% compound annual growth rate (CAGR), from $71.57M to $228.37M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.